Paradigm engaged FB Rice in the development, registration and prosecution of our patents in order to secure a strong IP position. Paradigm has registered for the BME product Zilosul (tmr) and respiratory product Rhinosul (tmr) for Allergic Rhinitis.
Paradigm’s patent coverages includes
BME for treatment of bone marrow edema lesions with Pentosan Polysulphate covering Australia, USA, Japan, China, Taiwan, Singapore and other countries across the Asia Pacific
MPS patented for treatment with Pentosan Polysulphate covering the same regions
Alphavirus patented for treatment with Pentosan Polysulphate covering the same regions
Respiratory Disease for treatment with Pentosan Polysulphate covering the same regions
Trademarks - Paradigm has trademarked it's proprietary formulations for Pentosan Polysulphate Sodium for treatment of bone marrow edema - Zilosul and Rhinosul.
Any other concerns, they have pretty well stitched it up IMHO
PAR Price at posting:
$1.43 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)